| scholarly article | Q13442814 |
| P50 | author | Frederick W. Miller | Q30510395 |
| Marc C Levesque | Q90560660 | ||
| Chester V. Oddis | Q114404222 | ||
| Rohit Aggarwal | Q125147565 | ||
| Lisa G. Rider | Q37373352 | ||
| Michael Harris-Love | Q55510370 | ||
| B J Feldman | Q72827547 | ||
| Richard J Barohn | Q89929903 | ||
| P2093 | author name string | Ann M Reed | |
| Dana P Ascherman | |||
| RIM Study Group | |||
| Andriy Bandos | |||
| P2860 | cites work | Two distinct cytokines released from a human aminoacyl-tRNA synthetase | Q22009128 |
| Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase | Q28141449 | ||
| Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients | Q33649923 | ||
| Polymyositis and dermatomyositis (second of two parts) | Q33909233 | ||
| Polymyositis and dermatomyositis (first of two parts) | Q33911013 | ||
| Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy | Q33975216 | ||
| Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies | Q34074602 | ||
| Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies | Q34242818 | ||
| Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies | Q34440026 | ||
| Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. | Q34518931 | ||
| Polymyositis: an overdiagnosed entity | Q34536136 | ||
| Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen | Q34564174 | ||
| Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial | Q34644962 | ||
| A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis | Q34728752 | ||
| Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies | Q35036195 | ||
| Defining Clinical Improvement in Adult and Juvenile Myositis. | Q35074992 | ||
| A randomized, pilot trial of etanercept in dermatomyositis | Q35206687 | ||
| The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses | Q35580535 | ||
| Long-term outcome in polymyositis and dermatomyositis | Q35638147 | ||
| International consensus on preliminary definitions of improvement in adult and juvenile myositis. | Q35833559 | ||
| The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. | Q36086954 | ||
| Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells | Q36371257 | ||
| Clinical characteristics and outcomes of juvenile and adult dermatomyositis | Q37284770 | ||
| Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index | Q37475947 | ||
| Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study | Q37761085 | ||
| Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. | Q37906737 | ||
| A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups | Q40743626 | ||
| Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy | Q41084662 | ||
| Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases | Q44301323 | ||
| Prognosis and mortality of polymyositis and dermatomyositis patients | Q46943629 | ||
| The randomized placebo-phase design for clinical trials | Q48867556 | ||
| Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. | Q51040689 | ||
| The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. | Q54526303 | ||
| Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. | Q54539256 | ||
| Survival, mortality and causes of death in inflammatory myopathies | Q56966975 | ||
| Reliability and validity of the myositis disease activity assessment tool | Q57752642 | ||
| Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study | Q60604106 | ||
| The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis | Q70432869 | ||
| Influence of age on characteristics of polymyositis and dermatomyositis in adults | Q77824765 | ||
| Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy | Q80974167 | ||
| Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients | Q83074680 | ||
| P433 | issue | 3 | |
| P921 | main subject | dermatomyositis | Q681160 |
| polymyositis | Q980926 | ||
| P304 | page(s) | 740-749 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis | |
| P478 | volume | 66 |
| Q64084577 | A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy |
| Q88166126 | Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity |
| Q38289816 | Advances in biomarkers for paediatric rheumatic diseases. |
| Q36484465 | Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials |
| Q33688739 | Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis |
| Q42632915 | Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort |
| Q52884348 | Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. |
| Q35779841 | Biologic predictors of clinical improvement in rituximab-treated refractory myositis |
| Q33795594 | Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. |
| Q91059371 | Classification and management of adult inflammatory myopathies |
| Q37617000 | Consensus-based recommendations for the management of juvenile dermatomyositis. |
| Q55284035 | Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. |
| Q38680762 | Current pharmacological treatment of idiopathic inflammatory myopathies |
| Q34501531 | Cutaneous dermatomyositis in the era of biologicals |
| Q88324782 | Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies |
| Q33874714 | Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan |
| Q36059517 | Diagnosis and treatment of inflammatory myopathy: issues and management |
| Q93080021 | Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis |
| Q53375302 | Editorial: A New Classification of Adult Autoimmune Myositis. |
| Q35833312 | Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial |
| Q97527779 | Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies |
| Q38597575 | Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms |
| Q38589301 | Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets |
| Q42450910 | Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide |
| Q30699742 | Immunotherapies for Immune-Mediated Myopathies: A Current Perspective |
| Q36152934 | In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome |
| Q52594789 | Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. |
| Q39027323 | Integrated classification of inflammatory myopathies |
| Q90296527 | Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment |
| Q41293529 | Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease |
| Q37095730 | Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics |
| Q39742692 | Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients |
| Q38281749 | Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies |
| Q92955292 | Myositis-Related Interstitial Lung Diseases: Diagnostic Features, Treatment, and Complications |
| Q40382867 | Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis |
| Q38646384 | Myositis-specific autoantibodies: an important tool to support diagnosis of myositis |
| Q92713786 | New insights into the treatment of myositis |
| Q47868107 | New ways to subclassify patients with myositis |
| Q36278027 | Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial |
| Q39425296 | Pharmacological management of dermatomyositis |
| Q47191067 | Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. |
| Q26798023 | Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies |
| Q47436112 | Recent developments on treatment strategies and the prognosis of dermatomyositis: a review |
| Q88528210 | Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis |
| Q40201287 | Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry |
| Q38802601 | Rituximab in autoimmune connective tissue disease-associated interstitial lung disease |
| Q88239776 | Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review |
| Q28077745 | Rituximab in the treatment of inflammatory myopathies: a review |
| Q26738952 | Selected aspects of the current management of myositis |
| Q38664251 | Serological subsets of juvenile idiopathic inflammatory myopathies--an update |
| Q90575845 | Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis |
| Q51700303 | Successful use of rituximab in a patient with refractory thrombotic thrombocytopaenic purpura complicated by polymyositis. |
| Q38603422 | The Clinical Features of Myositis-Associated Autoantibodies: a Review |
| Q38572045 | The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review |
| Q89586255 | The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity |
| Q88205700 | Treatment in myositis |
| Q38678257 | Treatment of Juvenile Dermatomyositis: An Update. |
| Q26796546 | Treatment of inflammatory myopathy: emerging therapies and therapeutic targets |
| Q38813275 | Update on the pharmacological treatment of adult myositis |
Search more.